Although cyclin D1 plays a major role during cell cycle progression and is involved in human tumourigenesis, its domain structure is still poorly understood. In the present study, we have generated a series of cyclin D1 N-and Cterminal deletion constructs. These mutants were used to de®ne the domains required for transformation of rat embryonal ®broblasts (REF) in cooperation with activated Ha-ras and and to establish correlations with de®ned biochemical properties of cyclin D1. Protein binding and REF assays showed that the region of the cyclin box required for the interaction with CDK4 as well as C-terminal sequences determining protein stability were crucial for transformation. Surprisingly, however, the N-terminal deletion of 20 amino acids which impaired pRb kinase activity did not aect the transforming ability of cyclin D1. Likewise, no eect on transformation was observed with mutants defective in p21 CIP interaction. These observations argue against a crucial role of pRb inactivation or p21 CIP squelching in cyclin D1-mediated transformation.
Introduction
The sequential activation of cyclin dependent kinases (CDKs) is essential for progression through the cell cycle. Cyclin D1 is one of the key regulators of CDK4 and CDK6, and is thought to have an important role in G 1 progression (Quelle et al., 1993; Resnitzky et al., 1994; Resnitzky and Reed, 1995) . The human cyclin D1 gene has initially been isolated in a screen for genes able to complement a triple cln defect in S. cerevisiae (Lew et al., 1991; Xiong et al., 1991) . It has also been identi®ed as part of a locus that is rearranged in human parathyroid adenoma (PRAD1) (Rosenberg et al., 1991a (Rosenberg et al., , 1993 Motokura and Arnold, 1993) . Subsequently it has been found in a more common rearrangement [the t(14 : 11) translocation] which plays a role in B-cell lymphomas (BCL1) (Rosenberg et al., 1991b (Rosenberg et al., , 1993 Motokura and Arnold, 1993) . Cyclin D1 is also ampli®ed and overexpressed in a number of breast and prostate tumours, colon adenocarcinomas and squamous cell carcinomas of the head and neck (Lammie and Peters, 1991; Buckley et al., 1993; Tam et al., 1994 , Han et al., 1998 , Maeda et al., 1998 . This circumstantial evidence for the involvement of cyclin D1 in oncogenesis was substantiated when it was shown that cyclin D1 cooperates with Myc family members in the induction of tumours in transgenic mice (Bodrug et al., 1994; Lovec et al., 1994a; Wang et al., 1994) and with Ha-ras in the transformation of cultured cells (Hinds et al., 1994; Lovec et al., 1994b) . Hinds et al. tested several point mutants of cyclin D1 to determine which interactions with known binding partners are necessary for transformation. A point mutation in the cyclin box that led to loss of CDK4 binding was shown to abrogate the transforming potential of cyclin D1, suggesting that the oncogenic potential of cyclin D1 is, at least in part, a consequence of its interaction with CDK4. The recent discovery of cyclin dependent kinase inhibitors (CDIs) (Pines, 1994) that associate with the cyclin/CDK complex de®nes additional potential targets that might be relevant for transformation by cyclin D1. In spite of the crucial role cyclin D1 plays in cell cycle control and tumourigeneis and the identi®cation of numerous interaction partners, its domain structure is still poorly understood. In the present study we have therefore analysed a set of Nand C-terminal deletion mutants in various assays to delineate functional domains in human cyclin D1.
Results

Transformation
In order to delineate the region in cyclin D1 that is required for transformation a series of N-and Cterminal deletion mutants was cotransfected with an activated Ha-ras gene (pEJ6.6ras) into secondary ®broblasts derived from day 14 rat embryos. Foci of transformed cells were counted 14 days after transfection (Figure 1) . A plasmid carrying the c-myc gene (pKo-c-myc) transfected together with Ha-ras was included as a control (Land et al., 1983) . Transfection of full length cyclin D1 or c-myc together with Ha-ras resulted in the expected number of foci (Lovec et al., 1994b) . Deletion of the N-terminal pRb binding domain (Dowdy et al., 1993; Ewen et al., 1993) did not decrease the oncogenic potential (D1/20-295), con®rming previous results with a point mutation in this region (Hinds et al., 1994) . A signi®cant drop in foci formation (60%) was observed when 40 amino acids were deleted (D1/40-295). An additional deletion of 16 amino acids (D1/56-295) reduced the transform-ing activity to the background activity observed with Ha-ras alone. Deletion of more than 39 amino acids from the C-terminus (D1/1-233) led to a similar reduction in focus formation. The minimal region required for full transformation by cyclin D1 therefore extends from amino acid 20 to amino acid 256.
CDK4 binding
The same deletion constructs were analysed for their ability to interact with CDK4 in a two-hybrid assay. Mouse CDK4 and human p21 CIP were inserted into the p414GALNVP16 vector. Each of these plasmids was introduced together with the dierent p416CYCNLexAcyclin D1 constructs into an S. cerevisiae strain carrying an integrated CYC1-LexAop-lacZ reporter construct. b-Galactosidase activity was measured by the o-NPG assay. N-terminal deletion of more than 20 amino acids (D1/40-295) resulted in a 50% reduced interaction with CDK4, which correlates with the reduced transforming potential of this mutant. Deletion of more than 40 amino acids (D1/56-295) reduced the binding by 87%, correlating with a further dramatic decrease in transformation (Figure 1 ). Upon deletion of more than 56 amino acids at the N-terminus of cyclin D1 (D1/91-295) no interaction with CDK4 was observed. Deletion of more than 39 amino acids from the Cterminus of cyclin D1 (D1/1-233) resulted in a reduction of binding activity by 40% and binding was lost when more than 125 C-terminal amino acids (D1/1-145) were removed.
The expression of several LexA-cyclin D1 fusion proteins was determined by immunoblotting ( Figure 2 and data not shown). This analysis showed that the Nterminal truncations (e.g., D1/91-295) were expressed at similar steady-state levels as full length LexA-cyclin D1. In contrast, the C-terminally truncated D1/1-145 protein was expressed at *sixfold lower levels (taking into account the smaller polypeptides which presumably represent degradation products). This raised the possibility that some of the data obtained with Cterminally truncated constructs might have been in¯uenced by eects on protein stability.
We therefore performed co-immunoprecipitation studies using in vitro translated 35 S-methionine labelled cyclin D1 deletion mutants and baculovirus expressed CDK4. Half of the mixture of mutant cyclin D1 protein and CDK4 was precipitated with a polyclonal a-cyclin D1 antibody (Figure 3a) and the other half of the reaction with a polyclonal a-CDK4 antibody ( Figure 3b ). Constructs D1/1-145 and D1/91-295 which showed no interaction in the two-hybrid assay could not be precipitated with the a-CDK4 antibody, although the labelled cyclin D1 translation products were detected with all constructs tested. In contrast, all other mutant proteins showed clear binding to CDK4. These binding properties were very similar for all functional proteins with the exception of D1/56-295 which showed two-to threefold reduced binding. This con®rms the data obtained by the two-hybrid analysis, but indicates that the *twofold reduced activity in the two-hybrid analysis of the C-terminally truncated D1/1-170, D1/1-196 and Figure 1 Schematic representation of cyclin D1 deletion mutants. The pRb interaction domain, the cyclin box, and the putative PEST sequence are indicated by grey, black and striped boxes, respectively. The ®rst column on the left indicates the number of foci obtained in two independent cotransfections of cyclin D1 mutants or c-myc with activated Ha-ras. The second column shows the ability of cyclin D1 proteins to interact with CDK4 in vitro (data from Figure 3b ). +:450% coprecipitation of CDK4 relative to wild-type cyclin D1; 7: no detectable coprecipitation of CDK4. The third and fourth columns indicate the relative units of bgalactosidase activity obtained for the interaction of the various cyclin D1 deletion mutants and CDK4 and p21 CIP in a two-hybrid assay, respectively. Mean normalised values (normalised to the interaction of full length cyclin D1 with CDK4) from three independent clones and independent measurements are given. The right-most column summarises the data obtained by pulse-chase experiments using transiently transfected, 35 S-labelled COS-7 cells. nd: not done D1/1-233 proteins might indeed be due to lower proteins levels. Taken together, these results show that the minimal region of cyclin D1 required for the interaction with CDK4 spans amino acids 56 ± 170 and that the adjacent region between residues 40 and 56 is required for ecient complex formation.
pRb kinase activity
We next addressed the question whether the transforming potential of cyclin D1 correlates with pRb kinase activity. To this end, we coexpressed the cyclin D1 wild-type and two truncated proteins together with CDK4 in a baculovirus system. The respective insect cell extracts were analysed by immunoblotting for cyclin D1 protein expression and for pRb kinase activity using a GST-pRb fusion protein as the substrate in an in vitro kinase assay (Figure 4) . The results clearly show that the N-terminal truncation of 20 amino acids abolished pRb kinase activity. Since the same mutant exhibited unimpaired transforming properties, these results indicate that pRb kinase activity is not essential for the induction of transformation. In contrast to the N-terminal truncation, the deletion of 39 amino acids from the C-terminus had only a marginal eect, if any, on kinase activity. Further C-terminal truncations could not be tested because the respective proteins were insoluble.
Interaction with p21 CIP
The interaction between cyclin D1 and p21 CIP was considerably weaker compared to the complex formation between cyclin D1 and CDK4 (6% for D1/1-295) in the yeast two-hybrid assay (Figure 1 ). This weaker binding has also been reported for coimmunoprecipitation of cyclin D1 and p21 CIP (Goubin and Ducommun, 1995) . A threefold decrease of the cyclin D1/p21 CIP interaction was observed upon deletion of the ®rst 20 amino acids of the N-terminus (D1/20-295) and binding was completely lost when additional amino acids were deleted. Deletion of 62 amino acids at the C-terminus (D1/1-233) did not aect binding of cyclin D1 to p21 CIP at all. Surprisingly, deletion of a further 37 amino acids (D1/1-196) resulted in a fourfold stronger interaction, suggesting that an inhibitory domain may have been deleted. Construct D1/1-145 showed no binding to p21 CIP at all. These data therefore indicate that the minimal region of cyclin D1 necessary for p21 CIP interaction spans amino acids 20 ± 170. 
Protein stability in mammalian cells
Wild-type cyclin D1 and six dierent deletion mutants were cloned into an expression vector containing an SV40 origin of replication and transfected into COS-7 cells. Twenty-four hours post-transfection, the cells were pulse-labelled for 45 min with 35 S-methionine and cyclin D1 protein was immunoprecitated at dierent times after 35 S-methionine removal (chase). To calculate the half-life values for the various proteins tested, signal intensities were quantitated by densitometry and plotted logarithmically against the respective chase interval. The data shown in Figure 1 clearly show that truncation of the C-terminus beyond amino acid 256 dramatically aects protein stability. While the longer proteins showed wild-type-like half-life values of *50 min, the half-life of D1/1-233 and D1/1-196 dropped to 15 and 5 min, respectively. Interestingly, removal of the putative destabilising PEST sequences near the C-terminus had no eect on protein stability, indicating that these motifs are not crucial determinants of cyclin D1 turn-over. In contrast to the Cterminal deletions, N-terminal truncations of up to 56 amino acids did not aect protein stability to any signi®cant extent. All mutants analysed showed exponential degradation kinetics (data not shown), indicating that the dierent half lives are not simply due to an overloaded degradation machinery.
Discussion
The results obtained in the present structure-function analysis are summarised in Figure 5 . Our study con®rms that the oncogenic activity of cyclin D1 is not due to the sequestration of pRb, since deletion of the interaction domain does not result in a decreased number of foci in rat ®broblasts (Figure 1 ). In addition, our results suggest that the pRb kinase activity is not required for transformation by cyclin D1 either, since the deletion of 20 amino acids from the N-terminus of cyclin D1 impaired pRb kinase activity without any detectable eect on focus formation (Figures 1 and 4) . It is unclear why this N-terminal truncation impairs pRb kinase activity, since the pRB interaction motif LXCXE motif seems to be dispensable (Dowdy et al., 1993) . In addition, mutation of the LXCXE motif does not change the in vivo phoshorylation state of pRb (Hinds et al., 1994) , and cyclin D1/20-295 still associates with CDK4 and has an intact second cyclin fold that is necessary for activation by CAK (Diehl and Sherr, 1997) . Even though this question cannot be answered at present, the lack of correlation between pRb kinase activity and transformation is intriguing and consistent with published data showing that S-phase entry due to overexpression of cyclin D/CDK4 is not dependent on pRb phosphorylation (Leng et al., 1997) . These observations suggest that pRb is not the only critical target for cyclin D1.
Previous data have indicated a crucial role for cyclin D1-CDK4 interaction, based on the analysis of a kinase-dead point mutant in the cyclin box. Our data Figure 4 pRb kinase activity of baculovirus-expressed cyclin D1-CDK4 complexes expressed in Sf9 cells. Top panel: immunoblot analysis of cyclin D1 levels. Bottom panel: in vitro kinase assay using a GST-pRB fusion protein as the substrate Figure 5 Schematic representations of human cyclin D1 and functional domains (black bars) identi®ed in the present study. Grey bars indicate regions in cyclin D1 that are not essential, but required for full activity. The center part of cyclin D1 was not analysed for its eect on protein stability are compatible with this observation, since the domain required for CDK4 interaction is contained within the cyclin D1 fragment that is crucial for transformation (Figures 1, 3 and 5) . Our results also extend previous observations, in that our data delineate the minimum region of cyclin D1 required for complex formation with CDK4. As expected, this region covers the entire cyclin box, but extends by about 20 amino acids in both directions. The same domain is involved in p21 CIP binding, but in this case the entire cyclin D1 Nterminus is needed for maximal interaction. The transformation-relevant N-terminal part of cyclin D1 is longer than the CDK4 interaction domain, suggesting that kinase activation might not be sucient for maximal transformation. We therefore extended our analysis to the interaction of cyclin D1 with p21 CIP , since squelching of p21 CIP may play a role in transformation. Our data, however, do not fully support such a notion, since the region required for transformation appears to be shorter than the p21 CIP interaction domain (Figures 1 and 5 ). Of course one has to be cautious about the establishment of correlations that are based on results stemming from dierent experimental systems.
Another surprising ®nding of our study is the observation that the PEST motif near the C-terminus apparently plays no detectable role in protein stability in mammalian cells (Figure 1 ). In contrast, the sequences located N-terminally to the PEST motif are crucial for protein stability, since their removal dramatically decreases the half-life of the protein in mammalian cells, and also leads to lower steady-state levels in yeast. The reason for this is unknown, but could be associated with the lack of a stable conformation or an increased accessibility to alternative degradative mechanisms like calpain protease degradation that has been shown to regulate cyclin D1 protein levels (Choi et al., 1997) . These data nevertheless provide a clear explanation for the requirement of the C-terminal region of cyclin D1 for transformation. In addition, this part of cyclin D1, which is required for transformation but not for CDK4 or p21 CIP binding, might harbour interaction domains for critical substrates of the cdk holoenzyme.
In summary, our study clearly suggest that the inactivation of pRb is not a critical step in cyclin D1-triggered transformation. In contrast, the CDK4 binding interface is crucial, which either points to other critical substrates of cyclin D1 kinase or interaction partner other that CDKs. That both scenarios are possible is suggested by published evidence. Thus, non-pRb substrates for cyclin D1-CDK4 have been identi®ed in mammary carcinoma cells (Sarcevic et al., 1997) , and the estrogen receptor has been shown to be activated by cyclin D1 in a CDK-independent fashion (Zwijsen et al., 1997) . Future investigations now have to address the question which pRB-unrelated mechanisms mediate the transforming potential of cyclin D1.
Materials and methods
Focus assays
REF assays were carried out essentially as described (Lovec et al., 1994b) . Frozen REFs were thawed, seeded at a density of 1610 6 per 80 cm 2 plate in Dulbecco-Vogt modi®ed Eagle's minimum essential medium (DMEM) supplemented with 10% fetal calf serum (FCS), and used for transfection the following day. Transfections were carried out by the calcium phosphate precipitation method (Graham and van der Eb, 1973) using 30 mg of DNA (Qiagen puri®ed) per dish. This included 10 mg of pEJ6.6 (Land et al., 1983) , 10 mg of pKo-myc or 10 mg of the dierent cyclin D1 constructs and 10 ± 20 mg high molecular weight carrier DNA (salmon sperm). Sixteen hours after transfection the cells were exposed to 25% glycerol in medium for 1 min. The next day cells were split at a 1 : 3 to 1 : 4 ratio depending on density, and assayed for focus formation after 14 days. The medium was changed every 4 days.
Two-hybrid assay
All experiments were performed with yeast strain YPH 499 (Sikorski and Hieter, 1989 ) (MATa ura3-52 lys2-801 amber ade2-101 ochre trpl-D63 his3-D200 leu2-D1) bearing a CYC1-lacZ reporter integrated at URA3. The CYC1-lacZ reporter plasmid with one lexA operator was constructed from the plasmid 1107 (Lech et al., 1988) . Transcriptional activation by the dierent LexA-cyclin D1 deletion mutants was measured by assaying b-galactosidase activity in cells grown in minimal selective medium as described (Ausubel et al., 1991) . In all experiments cells were grown in 3% w/v ra®nose until stationary and subsequently grown in media containing 2% w/v galactose, 1% w/v ra®nose and in media containing 2% glucose until mid-log phase. Data represent the average of three assays using three independent transformants. LexA constructs are based on the expression vector pRS416CYC1 (Mumberg et al., 1995) . The complete LexA repressor (amino acid 1 ± 202) was inserted as a XbaI/BamHI PCR fragment containing the simian virus 40 large tumour antigen nuclear localisation signal (NLS) (Met-Pro-Lys-Lys-LysArg-Lys-Val) (Dingwall and Laskey, 1991) at the Nterminus and three glycine spacer at the C-terminus. p416CYC1NLexA allows N-terminal fusion of bait proteins to LexA. Cyclin D1 N-terminal and C-terminal deletions were generated by using PCR fragments containing a 5' BamHI site followed by the natural ATG codon for the full length cyclin D1 and the C-terminal deletions, or a synthetic ATG for the N-terminal deletions, and a synthetic stop codon followed by a 3' EcoRI site. The dierent cyclin D1 fragments were cloned as BamHI/EcoRI fragments into the expression vector pCMV for REF assays. The BamHI/EcoRI were excised and fused in frame to the LexA-repressor in the yeast expression vectors p416CYC1LexA. The cyclin D1 fragments D1/1-295, D1/ 91-295, and D1/1-145 were also fused to LexA in p416MET25LexA (Jooss et al., 1994) . The fusions were veri®ed by DNA sequencing. VP16 constructs are based on the expression vector pRS414GAL1. The acidic activation domain of the herpes simplex virus VP16 trans-activator (amino acid 406 ± 488) (Triezenberg et al., 1988) was inserted as a XbaI/BamHI PCR fragment containing three glycines as a spacer at the C-terminus. Plasmid p414GALNVP16 allows N-terminal fusion of proteins to VP16 in all reading frames. A full length mouse CDK4 and a full length human p21 CIP clone with a 5' BamHI and 3' EcoRI site were generated by PCR and fused in frame to the acidic activation domain of HSV VP16 in 414GALNVP16. All PCR generated DNA fragments were veri®ed by sequencing. from 10 ml culture at an O.D. of 0.6 ± 0.8 by boiling the cells in 500 ml 50 mM Tris/HCl pH 6.8; 10 mM DTT; 2% SDS; 0.1% bromophenolblue and 10% glycerol. 1/10 of the high spin supernatant (15 min at 20 000 g) was used for immunoblot analysis as described (Ausubel et al., 1991) .
Baculovirus-expressed proteins
Baculovirus expressed CDK4 and cyclin D1 were prepared as described (Sewing and MuÈ ller, 1994) . Subcon¯uent SF-9 cells of a 75 cm 2 -¯ask were infected with CDK4 and cyclin D1-baculovirus simultaneously (MOI&10). Two days after infection, cells were scraped o the¯ask, washed twice with PBS and lysed in 250 ml kinase buer (50 mM HEPES, pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 0.1 mM PMSF, 10 mg/ ml leupeptin, 20 U/ml aprotinin, 0.1 mM NaF, 0.1 mM sodium orthovanadate) . One hundred mg of protein were used for immunoblotting and detection of Rb-kinase activity, respectively.
Immunoblotting of baculovirus-expressed cyclin D1
Extracts were separated by SDS ± PAGE on a 12% gel and transferred to nitrocellulose membranes. Filters were blocked with 5% non-fat dry milk in PBS for 30 min at room temperature. First (a-CycD1, sc-246, Santa Cruz Biotechnology, diluted 1/300) and secondary antibody (amouse-HRP, Sigma, diluted 1/3000) were incubated for 1 h each at 48C, followed by three washing steps with 0.05% Tween-20 in PBS, respectively. Development was performed using enhanced chemiluminescence according to the manufacturer (Amersham Corp.).
Protein kinase assay
Cell extracts, 500 ng of GST-pRb fusion protein (Santa Cruz Biotechnology), 25 mM of unlabeled ATP and 5 mCi g-32 P-ATP were incubated in a ®nal volume of 30 ml at 308C for 30 min. The reactions were stopped by adding GST-Sepharose (20 m1/reaction, Pharmacia) diluted in kinase buer supplemented with 10 mM EDTA. Sepharose was washed three times with EDTA containing kinase buer, boiled in SDS-sample buer, and proteins were separated by electrophoresis on a 10% acrylamide gel. Phosphorylated proteins were visualized by autoradiography of the dried gel.
Immunoprecipitations
Immunoprecipitations were carried out essentially as described (Sewing et al., 1993) .
Determination of protein stability
CMV promoter-cyclin D1 cDNA cassettes were subcloned into the pSPN vector containing an SV40 ori and transfected into subcon¯uent cultures COS-7 cells which stably express SV40 large-T antigen. 10 6 cells were transfected with 5 mg of plasmid DNA in 2.5 ml of DMEM, 10% NU serum (Collaborative Research), 100 mM chloroquine and 0.004% (w/v) DEAE-dextran. The transfection mix was withdrawn after 90 min and the cells were exposed for 2 min to 10% (v/v) DMSO in serumcontaining DMEM. Twenty-four hours later the cells were trypsinised and reseeded, and after another 24 h, labeled with 35 S-methionine and analysed by immunoprecipitation for cyclin D1 as described (Sewing et al., 1993) .
